These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 15648188)

  • 21. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.
    Heijnsdijk EA; Warner E; Gilbert FJ; Tilanus-Linthorst MM; Evans G; Causer PA; Eeles RA; Kaas R; Draisma G; Ramsay EA; Warren RM; Hill KA; Hoogerbrugge N; Wasser MN; Bergers E; Oosterwijk JC; Hooning MJ; Rutgers EJ; Klijn JG; Plewes DB; Leach MO; de Koning HJ
    Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1458-68. PubMed ID: 22744338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
    Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
    Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC).
    Kriege M; Brekelmans CT; Boetes C; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Manoliu RA; Holland R; de Koning HJ; Klijn JG
    Fam Cancer; 2001; 1(3-4):163-8. PubMed ID: 14574173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.
    Tilanus-Linthorst MM; Obdeijn IM; Hop WC; Causer PA; Leach MO; Warner E; Pointon L; Hill K; Klijn JG; Warren RM; Gilbert FJ
    Clin Cancer Res; 2007 Dec; 13(24):7357-62. PubMed ID: 18094417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing.
    Murphy CD; Lee JM; Drohan B; Euhus DM; Kopans DB; Gadd MA; Rafferty EA; Specht MC; Smith BL; Hughes KS
    Cancer; 2008 Dec; 113(11):3116-20. PubMed ID: 18932252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
    Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
    JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
    Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
    Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer.
    Lord SJ; Lei W; Craft P; Cawson JN; Morris I; Walleser S; Griffiths A; Parker S; Houssami N
    Eur J Cancer; 2007 Sep; 43(13):1905-17. PubMed ID: 17681781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
    Chompret A
    J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MRI in the early detection of breast cancer in women with high genetic risk.
    Trecate G; Vergnaghi D; Manoukian S; Bergonzi S; Scaperrotta G; Marchesini M; Ferranti C; Peissel B; Spatti G; Bohm S; Conti A; Costa C; Sporeni M; Podo F; Musumeci R
    Tumori; 2006; 92(6):517-23. PubMed ID: 17260493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial breast and ovarian cancers.
    Arai M; Utsunomiya J; Miki Y
    Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening and follow-up of the patient at high risk for breast cancer.
    Willey SC; Cocilovo C
    Obstet Gynecol; 2007 Dec; 110(6):1404-16. PubMed ID: 18055740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
    Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
    Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
    Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
    Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study.
    Evans DG; Lennard F; Pointon LJ; Ramus SJ; Gayther SA; Sodha N; Kwan-Lim GE; Leach MO; Warren R; Thompson D; Easton DF; Eeles R;
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2123-31. PubMed ID: 19567506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
    Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
    N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
    Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
    Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.